Non-invasive positive pressure ventilation (NIPPV) in patients with hypoxaemic-hypercapnic respiratory failure is attracting increasing interest here in Slovakia as well as in the neighbouring Czech Republic. In Western countries this treatment modality has been used in practice by respiratory physicians for decades. It is therefore necessary to pay attention to it and master it, so that we are able to help patients with hypercapnic respiratory failure effectively, even when it has causes other than COPD (chronic obstructive pulmonary disease).
Introduction
We define NIPPV, as a broader term, as the application of ventilatory support with continuous positive pressure at two different levels (BiPAP – bilevel positive airway pressure) or in the form of intermittent positive pressure (IPPB – intermittent positive pressure breathing). It is applied via a nasal, oral, combined (oronasal) or full-face mask, or possibly via a tracheostomy cannula (1). Applying positive pressure at two levels creates a pressure gradient of the air flowing into the alveoli. This is pressure ventilatory support, in which the pressure generated by the device achieves a certain flow, with which we reach the target volume during inspiration. Since lung resistance differs to some extent with each breath, at the same pressure we achieve slight differences in tidal volumes (Vt) during the individual breathing cycles.
For life-sustaining treatment it is best to use ventilators designed for DUPV (home mechanical ventilation) applied via an oronasal mask, i.e. in non-invasive ventilation mode. Today these devices have reached a sophisticated level, so they can usually provide a sufficiently wide range of ventilation modes. Thanks to the high technical standard of this range of ventilators, the treatment settings of the device can be titrated precisely, which makes mask ventilation more comfortable and, above all, safer. At the same time we must constantly keep the patient’s safety, the effectiveness of treatment and the patient’s comfort in mind.
Characteristics
Ventilation itself in a patient with hypercapnic respiratory failure due to COPD is ideally applied with a single-limb leak circuit, usually in S/T mode. A leak circuit naturally requires the device to compensate for these leaks through the mask and the tubing. After being set by the physician, devices for DUPV automatically correct the change in lung resistance when the patient changes position. Titration of the parameters naturally has to be carried out on inpatient wards or in the ICU (JIS), as it requires feedback from the patient, blood gas checks, monitoring of the patient and comprehensive management.
COPD and its consequences
Obstruction of the airways leads to increased pulmonary resistance, which we have to overcome with inspiratory pressure (IPAP). Prolonged expiration leads to a markedly prolonged time needed for sufficient exhalation, i.e. down to the level of the end-expiratory volume (ERV); on the ventilator the expiration time is labelled Te. Premature collapse during exhalation leads to air trapping, emphysema promotes hyperinflation, and the patient’s chest is therefore held more in an inspiratory position. We must therefore leave the patient a sufficiently long time to exhale, the need for which is individual, so that they can reach the ERV level and thus eliminate the influence of the factors mentioned above. A person in respiratory insufficiency has exhausted respiratory muscles; the ventilation modes used can considerably reduce the work of the respiratory muscles in patients with restrictive as well as obstructive ventilatory disorders. Respiratory insufficiency in patients with COPD is caused by a reduction in minute ventilation and an increase in the ratio between dead-space ventilation and minute ventilation (2). With ventilatory support, their respiratory rate decreases significantly because of the prolonged expiration and, consequently, the longer breathing cycle. Thanks to this, the work of the respiratory muscles is relieved and the respiratory parameters improve. A secondary effect of the treatment is improved oxygenation.
Titration of ventilation parameters
The first parameter is IPAP (inspiratory positive airway pressure), the pressure during inspiration, thanks to which we achieve the required tidal volume (Vt) and with which we overcome the resistance of the lungs, bronchi and chest wall and the pressure of the diaphragm (2). The size of Vt is influenced by the inspiratory time (Ti) and the IPAP level. The higher the pressures we use, the sooner we can expect side effects in the patient such as flatulence, dryness of the mucous membranes of the upper airways or, conversely, rhinorrhoea, pressure in the paranasal sinuses, etc. The target tidal volume should be 8 ml/kg. The greater the obstruction of the airways, the higher the pressure that is of course needed to overcome airway resistance so that we can achieve the appropriate Vt. EPAP (expiratory positive airway pressure) helps us keep the small and medium airways open during exhalation, i.e. it protects them from collapse. The effective pressure is the difference between IPAP and EPAP. Patients tolerate EPAP values above approximately 7 kPa with great discomfort, and such pressure levels are not recommended. We use a steep inspiratory ramp and, conversely, in view of the prolonged exhalation, a flat expiratory ramp, which is typical of COPD.
One of the key setting parameters is the expiration time (Te). Eliminating air trapping makes it possible to use the physiological resting tidal volume and to ventilate CO2 out effectively. The optimal setting of the length of Te is based on a mandatory prolongation of the expiration time, ideally all the way to the level of zero flow and zero volume at the end of exhalation. Exhalation in a patient with COPD is non-linear; artefacts form, a kind of turbulence during exhalation. Because sudden pressure jumps occur during exhalation, the device would detect this as an inspiratory effort and would start supporting inspiration. Since this is an artefact, that is not our aim. Without such a setting, artefacts during exhalation therefore lead to false triggering of inhalation. The aim is to let the patient exhale as fully as possible (to the ERV level). We set maximum or submaximal sensitivity of the inspiratory trigger for maximum relief of the respiratory muscles, so that even minimal effort on the part of the patient will lead to inhalation. The air trap control function helps us filter out artefacts at the beginning, and according to how often this function is activated and the length of Te, the inspiration blocking time can be set in more detail. This requires the use of the inspiratory trigger blocking function (trigger lockout) for a defined duration of exhalation (Te). We set the trigger lockout time approximately 0.2-0.3 s below the patient’s real expiration time. Thanks to this, only flow artefacts that falsely trigger a premature inhalation are blocked, while the patient’s real inspiratory effort is not blocked. The elimination of air trapping with gradual prolongation of Te is monitored using the flow/volume loop. Our target is to achieve zero dynamic hyperinflation without affecting the patient’s comfort. The resulting Te is individually optimised for the given patient (5). In this way we obtain a physiological resting tidal volume without air trapping. Te values are not infrequently around 3.5-5 s. The respiratory rate must therefore inevitably fall; the patient breathes more slowly but much more effectively, which leads to long-term maintenance of normocapnia with intermittent therapy. By eliminating air trapping we significantly reduce the IPAP required for a physiological Vt; lower IPAP levels lead to much greater patient comfort during long-term therapy with a low incidence of side effects. IPAP can be reduced further with a sufficiently long Ti, because to create the target Vt a lower pressure delivered over a longer time is enough to achieve the same volume as a higher pressure over a shorter time, all with regard to the patient’s needs. By reducing the respiratory rate we achieve maximum relaxation of the respiratory muscles, so that the muscles conserve energy for daily activities outside the therapy sessions. With settings of this kind, 6-8 hours of application during the day is usually sufficient to keep the disease stable.
Respiratory tract resistance differs between the lying and upright positions. Mainly due to the pressure of the diaphragm and the abdominal organs, resistance increases when lying down, which is why we have to overcome it with the IPAP value. Once the compensation function is set on the device, it will compensate for resistance as needed when the patient’s position changes, by gradually increasing IPAP until the target volume is reached. We can then be sure that the patient will be sufficiently ventilated at home.


The device can display the current tidal volumes graphically, from which we can read the trapped volume, Vt, minute ventilation and more. Fig. 5 shows the tidal volume curve, which reaches zero values at the end of exhalation, i.e. there is no air trapping (red arrows).

Patient group
In a group of 14 patients with hypercapnic respiratory failure due to COPD we can see the settings described above in practice. The group consisted of 9 men and 5 women, aged from 57 to 87 years. Table 1 shows the IPAP values, which reached a minimum of as little as 6.8 hPa and a maximum of 16.8 hPa, and these values were sufficient for the respective patients to ventilate out pCO2 effectively. The value of 16.8 hPa IPAP belongs specifically to a patient with obesity, which explains the need for a higher pressure. EPAP values ranged from 4 – 6.6 hPa. The spontaneous respiratory rate oscillated around 10 breaths/min on average. On average, a Ti of 1.6 s was sufficient time for inhalation, and Te, one of the most important parameters, averages 3.8 s, with a range of 2 – 5.3 s. This is a time that is so-called tailor-made for each patient according to their personal needs; patients manage it without feeling restricted or any other discomfort. In the group, 6 people needed a Te above 4.5 s. Trigger lockout was set on average at 3.6 s, with the minimum and maximum ranging from 1.8 to 5 s, which is on average 0.2 s less than the actual time needed for exhalation (Te). The I:E and Ti/T parameters are ratios that result from the setting of the other parameters. With the parameters described, we achieved an average Vt of 550 ml, which corresponds to 8ml/kg. Since ventilation takes place via a leak circuit and we ventilate the patients with low IPAP pressures, the leaks are correspondingly low, averaging 31 l/min with a maximum of 40 l /min, which represents a very comfortable result.
Graph 1 shows how the pCO2 values developed. The initial values are mostly from 8 to 10 kPa; the lowest value was 7.5 kPa. After 2-3 days of ventilation, the values in patients fall to between 5.3 – 7.5 kPa. After longer-term ventilation of the order of 2-3 weeks, people on this treatment reach normal or nearly normal pCO2 values, which means that they have mild hypercapnia or no hypercapnia at all. The duration of treatment in the group ranges from 6 to 9 hours a day; most patients use it during the night.

Conclusion
In patients with COPD who suffer from hypoxaemic-hypercapnic respiratory failure, non-invasive ventilation is indicated with the aim of long-term home use. If the patient has reached a pCO2 of more than 7.3 kPa at any time during the day, they are indicated for long-term home ventilation with a DUPV ventilator, combined with long-term home oxygen therapy. If the patient does not meet this criterion, the additional criteria are: PaCO2 ?7.3 kPa if nocturnal desaturations of SaO2 ? 88% are found for more than 5 min. while receiving O2?2 l/min, or two or more hospitalisations a year for respiratory failure (1).
Discussion
It is very positive that conditions for providing this kind of treatment have now been created in our country. Non-invasive ventilation brings encouraging results that can give the patient back a relatively satisfactory quality of life and thus significantly postpone terminal respiratory failure. It is a life-sustaining treatment without which such patients would die. From personal experience I can say that patients rate the benefit of this treatment very positively, because shortly after starting it they all realise what a marked change it means for them in terms of stabilising the disease, at a time when bronchodilator and other supportive treatment has already been exhausted. This is also borne out by the results in the group of patients from our department. Last but not least, mastering the technique of ventilation therapy increases professional credibility among respiratory physicians, since the indication is in our hands, together with the specialties of OAIM (anaesthesiology and intensive care) and neurology. In this way we will contribute to a broader range of care provided at our departments, which in the near future should become a matter of course, as it is in Western countries, where this treatment is an absolute standard.
The undeniable advantages of low-pressure ventilation are that the risk of pneumothorax, the most serious complication of pressure-supported ventilation, is significantly reduced. The patient does not suffer the discomfort of high pressures and the resulting high flow in the upper airways. A gentler tightening of the mask to the face with the head straps is sufficient, which significantly reduces the formation of pressure sores and skin pressure marks, and the incidence of flatulence and meteorism is much lower. This method of ventilation comes close to the physiology of breathing and is more comfortable overall, which is important especially in the context of long-term use; patients show very good adherence to the treatment. Regular ventilation thus enables sufficient oxygenation and the elimination of symptoms.
References:
- Hájková, M., Mucska, I., Metodické odporúčanie hlavného odborníka MZ SR pre odbor pneumológia a ftizeológia - Indikácie neinvazívnej pozitívnej pretlakovej ventilácie (NIPPV), 2015
- Chlumský, J., Doporučení pro použití neinvazivní ventilační podpory
- Gobel, Ch., Mechanical Ventilation for COPD, Weinmann Medical Technology
- Simonds, A. K., ERS practical Handbook, Noninvasive Ventilation, 2015
- Pastucha R., Practical tips for ventilation settings of home-care, non-invasive, spontaneus breathing COPD patient with goal of effective airtrapping control, Weinmann, Hamburg, lecture, 2016
Author: MUDr. Peter Kajtár
Department of Respiratory Medicine,
NsP Prievidza so sídlom v Bojniciach
Contact: Department of Respiratory Medicine, NsP Prievidza so sídlom v Bojniciach, Nemocničná 2, 972 01 Bojnice,
MUDr. Peter Kajtár, e-mail: pejo.pajo@gmail.com
Created 29/09/2026 · last updated 22/10/2026